Association Between Time to Initiation of Adjuvant Chemotherapy and Survival in Colorectal Cancer

Biagi, James; Raphael, Michael J.; Mackillop, William J.; Kong, Weidong; King, Will D.; Booth, Christopher M.

doi:10.1001/jama.2011.749

Cited by 583 publications

(421 citation statements)

References 31 publications

Supporting

Mentioning

398

Contrasting

Unclassified

Order By: Relevance

“…In einer retrospektiven Analyse von Kohortenstudien [868]. wurde eine inverse Korrelation zwischen dem Zeitpunkt des Beginns einer adjuvanten Chemotherapie und dem Überleben berechnet.…”

Section: Hintergrundunclassified

S3-Leitlinie – Kolorektales Karzinom

Schmiegel

Buchberger

Follmann³

et al. 2017

Z Gastroenterol

151

View full text Add to dashboard Cite

“…In einer retrospektiven Analyse von Kohortenstudien [868]. wurde eine inverse Korrelation zwischen dem Zeitpunkt des Beginns einer adjuvanten Chemotherapie und dem Überleben berechnet.…”

Section: Hintergrundunclassified

S3-Leitlinie – Kolorektales Karzinom

Schmiegel

Buchberger

Follmann³

et al. 2017

Z Gastroenterol

151

View full text Add to dashboard Cite

“…This turnaround time has been recommended in other guidelines for molecular tumor testing. 105,126,127 Ideally, the transitional time between test ordering, tissue block selection, block retrieval, and shipment to the performing laboratory should be included in the 10-day timeframe. Consequently, laboratories should make every effort to minimize delays in securing appropriate tissue blocks for testing.…”

Section: Postanalytical Variablesmentioning

confidence: 99%

Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology

Sepulveda

Hamilton²,

Allegra

et al. 2017

Archives of Pathology &Amp; Laboratory Medicine

126

101

View full text Add to dashboard Cite

Objectives.-To develop evidence-based guideline recommendations through a systematic review of the literature to establish standard molecular biomarker testing of colorectal cancer (CRC) tissues to guide epidermal growth factor receptor (EGFR) therapies and conventional chemotherapy regimens.Methods.-The American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology convened an expert panel to develop an evidence-based guideline to establish standard molecular biomarker testing and guide therapies for patients with CRC. A comprehensive literature search that included more than 4,000 articles was conducted.Results.-Twenty-one guideline statements were established.Conclusions.-Evidence supports mutational testing for EGFR signaling pathway genes, since they provide clinically actionable information as negative predictors of benefit to anti-EGFR monoclonal antibody therapies for targeted therapy of CRC. Mutations in several of the biomarkers have clear prognostic value. Laboratory approaches to operationalize CRC molecular testing are presented.

show abstract

“…The timing of adjuvant chemotherapy may also have a considerable effect on survival outcomes and has been largely overlooked in the present studies. Several metaanalyses showed that the longer the chemotherapy is delayed the shorter survival is in patients with colorectal cancer [50,51] . One of the reasons why colon cancer responds to adjuvant chemotherapy and rectal does not may be prompt administration of adjuvant chemotherapy [9] .…”

Section: Potential Pitfalls Of the Current Evidencementioning

confidence: 99%

Adjuvant chemotherapy for rectal cancer: Is it needed?

Milinis

Thornton

Montazeri

et al. 2015

WJCO

View full text Add to dashboard Cite

Adjuvant chemotherapy has become a standard treatment of advanced rectal cancer in the West. The benefits of adjuvant chemotherapy after surgery alone have been well established. However, controversy surrounds the use adjuvant chemotherapy in patients who received preoperative chemoradiotherapy, despite it being recommended by a number of international guidelines. Results of recent multicentre randomised control trials showed no benefit of adjuvant chemotherapy in terms of survival and rates of distant metastases. However, concerns exist regarding the quality of the studies including inadequate staging modalities, out-dated chemotherapeutic regimens and surgical approaches and small sample sizes. It has become evident that not all the patients respond to adjuvant chemotherapy and more personalised approach should be employed when considering the benefits of adjuvant chemotherapy. The present review discusses the strengths and weaknesses of the current evidence-base and suggests improvements for future studies.

show abstract

Association Between Time to Initiation of Adjuvant Chemotherapy and Survival in Colorectal Cancer

Abstract: In a meta-analysis of the available literature on time to AC, longer time to AC was associated with worse survival among patients with resected colorectal cancer.

Cited by 583 publications

References 31 publications

S3-Leitlinie – Kolorektales Karzinom

S3-Leitlinie – Kolorektales Karzinom

Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology

Adjuvant chemotherapy for rectal cancer: Is it needed?

Contact Info

Product

Resources

About